Testosterone Lawsuit News

Sponsored by Hissey-Kientz - Committed to protecting your legal rights.
Call us Toll Free at 866-275-4454 for a FREE Consultation
Help and information about Testosterone lawsuit issues.

Low T drug sales could reach $5 billion by 2017

September 12th, 2014

Sales of testosterone boosters, or “Low T” drugs, could reach $5 billion by 2017, according to the New York Times. Testosterone boosters, which include drugs such as AndroGel and Androderm, reached $2 billion in sales in 2012 —Low T prescriptions have tripled since 2001.

Many doctors have expressed concern at the growing rate of testosterone booster prescriptions, particularly to patients who have not been clinically tested for low testosterone, also known as hypogonadism. As many as 25% of low testosterone drugs are prescribed without a patient receiving a blood test necessary for the diagnosis.

Recent studies have found that patients could be at an increased risk of serious side effects associated with testosterone boosters. Manufacturers are now facing multiple testosterone booster lawsuits alleging that the companies failed to warn doctors and patients of the increased risks of heart attacks and stroke associated with Low T drugs.

Contact Us Today for a Free Consultation.

I am currently represented by an attorney.
*Required fields